Edgar Lomax Co. VA Sells 182,473 Shares of Pfizer Inc. $PFE

Edgar Lomax Co. VA trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 23.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 610,007 shares of the biopharmaceutical company’s stock after selling 182,473 shares during the quarter. Edgar Lomax Co. VA’s holdings in Pfizer were worth $15,543,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Grey Fox Wealth Advisors LLC purchased a new position in shares of Pfizer in the 3rd quarter valued at $29,000. Howard Hughes Medical Institute bought a new stake in Pfizer during the second quarter valued at about $30,000. Darwin Wealth Management LLC purchased a new position in Pfizer in the second quarter valued at about $32,000. Evelyn Partners Asset Management Ltd bought a new position in Pfizer in the second quarter worth about $33,000. Finally, True Wealth Design LLC lifted its position in shares of Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 974 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.0%

NYSE:PFE opened at $26.63 on Friday. The company has a market capitalization of $151.43 billion, a P/E ratio of 19.58 and a beta of 0.47. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The firm has a fifty day simple moving average of $26.26 and a 200-day simple moving average of $25.46.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same quarter last year, the business posted $0.63 EPS. The firm’s quarterly revenue was down 1.2% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. Pfizer’s dividend payout ratio is currently 126.47%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Federal judge approved a settlement awarding Pfizer $29 million related to the SEC’s 2013 insider‑trading case involving SAC Capital, closing a long‑running legal dispute and delivering a modest one‑time cash gain. Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund
• Positive Sentiment: Argus Research upgraded PFE to Buy with a $35 target, highlighting encouraging progress in Pfizer’s GLP‑1 obesity program and its oncology pipeline — a bullish catalyst for longer‑term revenue growth expectations. Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline
• Positive Sentiment: Investor writeups note portfolio renewal progress and attractive dividend yield for patient investors, framing Pfizer as a value/dividend play while its pipeline rebuild continues. Pfizer’s Portfolio Renewal In Progress – High Yields For The Patient
• Neutral Sentiment: Some outlets note the stock is down modestly since the last earnings release and are asking whether it can rebound — a monitoring signal rather than fresh news. Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound?
• Neutral Sentiment: Telescope Innovations installed a second self‑driving lab at Pfizer — a partnership update that points to operational/automation improvements but is unlikely to move near‑term revenues. Telescope Innovations Installs Second Self-Driving Lab at Pfizer
• Neutral Sentiment: Valuation pieces note divergence between long‑term return expectations and DCF views, signaling mixed investor opinions on fair value and outlook. A Look At Pfizer (PFE) Valuation As Long Term Returns And DCF Views Diverge
• Negative Sentiment: Analysis highlights structural growth challenges — falling COVID revenues, upcoming patent expirations and pricing/IRA headwinds — that could pressure sales and margins if new launches don’t scale. Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations?
• Negative Sentiment: Opinion pieces warn of “obesity hype” and potential vaccine policy shocks that could create volatility around expectations for new GLP‑1 products and vaccine revenues. Pfizer: Obesity Hype And Vaccine Policy Shocks

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on PFE shares. Citigroup assumed coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective on the stock. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a report on Monday. Barclays began coverage on Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target on the stock. TD Cowen reissued a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Finally, Royal Bank Of Canada assumed coverage on Pfizer in a research report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.05.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.